{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:16:05Z","timestamp":1767212165119,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T00:00:00Z","timestamp":1549065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12253-019-00607-2","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T01:43:43Z","timestamp":1549071823000},"page":"1615-1620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed\/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-056X","authenticated-orcid":false,"given":"Gergely","family":"Varga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Kosztol\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Szomor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Be\u00e1ta","family":"De\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rk","family":"Plander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Szendrei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e1r\u00f3czy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"B\u00e1tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nika","family":"Pet\u0151","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,2]]},"reference":[{"issue":"17","key":"607_CR1","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, di Bacco A, Hui AM, van de Velde H, Richardson PG (2016) Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"10","key":"607_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","volume":"102","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, di Bacco A, van de Velde H, Richardson PG, Moreau P (2017) Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1. Haematologica 102(10):1767\u20131775","journal-title":"Haematologica"},{"issue":"4","key":"607_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11523-017-0504-7","volume":"12","author":"ZT Al-Salama","year":"2017","unstructured":"Al-Salama ZT, Garnock-Jones KP, Scott LJ (2017) Ixazomib: a review in relapsed and\/or refractory multiple myeloma. Target Oncol 12(4):535\u2013542","journal-title":"Target Oncol"},{"key":"607_CR4","unstructured":"Terpos E, Maouche N, Minarik J et al (2017) \"Real world\" data on the efficacy and safety of Ixazomib in combination with Lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a combined study from the Greek, Czech and UK databases. Blood, 130(Suppl 1), 3087"},{"key":"607_CR5","unstructured":"Ziff M, Cheesman S, Kyriakou C (2017) Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma. EHA 2017 Abstract 1975"},{"key":"607_CR6","unstructured":"Terpos E, Katodritou E, Kotsopoulou M (2017)\u201cReal world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a study of the Greek myeloma study group. EHA 2017 Abstract 1249"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"X Leleu","year":"2018","unstructured":"Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosi\u00f1ol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG (2018) Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol [Epub ahead of print] 93:985\u2013993","journal-title":"Am J Hematol"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40273-018-0644-3","volume":"36","author":"X Armoiry","year":"2018","unstructured":"Armoiry X, Connock M, Tsertsvadze A, Cummins E, Melendez-Torres GJ, Royle P, Clarke A (2018) Ixazomib for relapsed or refractory multiple myeloma: review from an evidence review group on a NICE single technology appraisal. Pharmacoeconomics [Epub ahead of print] 36:1073\u20131081","journal-title":"Pharmacoeconomics"},{"key":"607_CR10","first-page":"1","volume":"29","author":"P Hari","year":"2018","unstructured":"Hari P, Lin HM, Zhu Y et al (2018) Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed\/refractory multiple myeloma. J Med Econ 29:1\u20136 [Epub ahead of print]","journal-title":"J Med Econ"},{"issue":"24","key":"607_CR11","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG (2017) Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130(24):2610\u20132618","journal-title":"Blood"},{"issue":"3","key":"607_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clml.2017.12.011","volume":"18","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Kaufman JL, White D, Cook G, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A (2018) A comparison of the efficacy of immunomodulatory-containing regimens in relapsed\/refractory multiple myeloma: a network meta-analysis. Clin Lymphoma Myeloma Leuk 18(3):163\u2013173","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-019-00607-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T19:13:08Z","timestamp":1580584388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-019-00607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,2]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s12253-019-00607-2","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"type":"print","value":"1219-4956"},{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2019,2,2]]},"assertion":[{"value":"23 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}